Bookmark
Print
Recommend
  • Home
  • About PBS/IC
    • Overview
    • Nomenclature
    • Causes
    • Diagnosis
      • Overview
      • Diagnostic flow
      • NIDDK
      • Differential diagnosis
    • Management
    • Patients
      • Patient quotes
      • Case studies
    • COB Foundation Survey
      • Overview
      • Diagnosis
      • Symptoms
      • Quality of life
      • Economic impact
    • Clinical Phenotyping
      • Background to UPOINT
      • What is UPOINT
      • UPOINT research
    • References
  • Product information
    • Overview
    • Efficacy
      • Study 1
      • Study 2
    • Tolerability
    • Volume
    • Optimum dose of chondroitin sulfate
    • Budget impact
    • Mode of Action
    • Rationale for using chondroitin sulfate for PBS/IC
      • Importance of bladder GAG layer
      • Importance of chondroitin sulfate in bladder wall GAG layer
      • Dr Hurst Presentation video
    • How to administer Uracyst
    • Recommended treatment plan
    • References
  • Resources
  • KOL webcast
  • Prescribing information & adverse incident reporting
  • Request a call back

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Dr Nickel
Interview

Click here
to watch the
interview in full

MOA
Animation

Watch the
mode of action video now

           Email
           updates

Sign up today and receive regular website updates

Where am I: Product information > Optimum dose of chondroitin sulfate

Optimum dose of chondroitin sulfate

Uracyst® may provide the optimum dose of chondroitin sulfate4,5

Uracyst (2% chondroitin sulfate) is formulated with 5 times more chondroitin sulfate per treatment than the currently available 0.2% formulation of intravesical chondroitin sulfate.

Brand

Gepan

Uracyst

Concentration of solution with chondroitin sulfate

0.2%

2.0%

Volume of solution per vial

40ml

20ml

Equivalent amount of chondroitin sulfate per vial

80mg

400mg


Results from an experimental animal study suggest that the optimum uptake of chondroitin sulfate in the human bladder would be at instillation doses of approximately 300mg.4,5 This indicates that the dosage provided by Uracyst, i.e. 400mg, should be sufficient for the damaged bladder to reach saturation point of chondroitin sulfate and that 80mg may be insufficient. 4,5

As can be seen from the graph below, uptake of intravesical chondroitin sulfate by damaged bladder is x 2.6-fold greater at a dose of 400mg compared to 80mg.4

These figures are based on values from damaged rat bladder which have been extrapolated to human bladders.

Binding of chondroitin sulfate to acid-damaged bladder4

GraphView graph

Home | About PBS/IC | Product information | Resources | KOL webcast | Prescribing information & adverse incident reporting | Request a call back | Contact us | Privacy | Sitemap | Copyright